FSD PHARMA B (0K9.F)
| Previous Close | 0.4945 |
| Open | 0.4255 |
| Bid | 0.4275 x N/A |
| Ask | 0.4685 x N/A |
| Day's Range | 0.4255 - 0.4255 |
| 52 Week Range | 0.4120 - 1.2450 |
| Volume | |
| Avg. Volume | 113 |
| Market Cap | 18.21M |
| Beta (5Y Monthly) | 0.91 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | May 10, 2024 - May 14, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ACCESSWIREFSD Pharma Provides Update from Celly Nu’s Partnership with Six+One for unbuzzd(TM)
TORONTO, ON / ACCESSWIRE / April 25, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), provides an update by way of a news release issued by Celly Nutrition Corp. ("Celly Nu"), and its launching of unbuzzd™, an innovative beverage ...
- ACCESSWIRE
FSD Pharma Provides Another Update on Celly Nu's Anticipated Launch of unbuzzd(TM)
TORONTO, ON / ACCESSWIRE / April 22, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), provides an update by way of a news release issued by Celly Nutrition Corp. ("Celly Nu"), and its launching of unbuzzd™, an innovative beverage ...
- ACCESSWIRE
FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products
TORONTO, ON / ACCESSWIRE / April 17, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments ...
